CN101167929A - Method for producing high-density lipoprotein biological regulator - Google Patents
Method for producing high-density lipoprotein biological regulator Download PDFInfo
- Publication number
- CN101167929A CN101167929A CNA2007101444353A CN200710144435A CN101167929A CN 101167929 A CN101167929 A CN 101167929A CN A2007101444353 A CNA2007101444353 A CN A2007101444353A CN 200710144435 A CN200710144435 A CN 200710144435A CN 101167929 A CN101167929 A CN 101167929A
- Authority
- CN
- China
- Prior art keywords
- vitamin
- density lipoprotein
- raw material
- high density
- technological process
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention discloses a process for producing a high density lipoprotein biological adjuster. The raw material and the process flow are that the raw material comprises alanine 2%, lysine 3%, ornithine 7%, glutamine 7%, phospholipid powder 10%-15%, evening primrose 5%, L-carnitine 3.8%, 2-aminoethane-sulfonic acid 10%, acetylcholine 2%, astragalus root 3%, dioscorea japonica 3%, chuanxiong rhizome 2%, prepared rehmannia root 3%, hirudo powder 2.93%, organic selenium 0.01%, tervalence organic chromium 0.01%, vitamin E 0.5%, niacinamide 0.5%, vitamin B1 0.05%, vitamin B2 0.05%, vitamin B6 0.05%, and vitamin B12 0.1%, further the rest materials of the invention are complete miscibility complete proteins active peptide, just like complete miscibility soy protein peptide. The medicament type can be water-paste pills and tablets. The process flow is the process of the conventional water-paste pills and tablets. Via the high density lipoprotein biological adjuster, the content of the high density lipoprotein in the animals can be increased.
Description
Technical field:
The present invention relates to a kind of biological regulator, a kind of specifically production method that improves the biological regulator of animal body middle-high density lipoprotein content.
Background technology:
High density lipoprotein is inherent a kind of apolipoprotein in the animal body, is that interior blood fat of body and cholesterol are to the necessary apolipoprotein of external discharge.From formation, it is consistent with the constituent of Chylomicron, very low density lipoprotein (VLDL), low density lipoprotein, LDL.All constitute by protein, this ester of glycerol, cholesterol, these four kinds of materials of phospholipid.But difference is: the content of triglyceride of high density lipoprotein is compared minimum with Chylomicron, very low density lipoprotein (VLDL), low density lipoprotein, LDL, and cholesterol level is higher than very low density lipoprotein (VLDL) and Chylomicron.The protein of high density lipoprotein is compared the highest with content of phospholipid with low density lipoprotein, LDL, very low density lipoprotein (VLDL) and Chylomicron.The density of high density lipoprotein is compared the particle diameter minimum with Chylomicron, very low density lipoprotein (VLDL), low density lipoprotein, LDL, the density maximum with particle diameter.Wherein Chylomicron is kind of the lipochondrion from food, mainly contains ectogenic triglyceride, and its metabolism is very fast, and the normal person can full scale clearance after general 12 hours.And its granule is very big, even the endarterium damage, it also can't pass.Therefore it and arteriosclerosis relation is little.Very low density lipoprotein (VLDL) is that liver is synthetic, and containing maximum is triglyceride (endogenic triglyceride).It is cholesterol that low density lipoprotein, LDL contains maximum.These two kinds of hdl particles are less, are easy to enter the arterial wall of damage.Usually too much cholesterol carrying is piled up to arterial wall.Their destructivenesses are very big, and people are referred to as " atherosclerosis lipoprotein " or " cardiovascular and cerebrovascular disease virulence factor ".And the content of the protein of high density lipoprotein and phospholipid is maximum and particle diameter is minimum, the density maximum.The inner membrance of its penetrable arterial blood tube wall, resolving into molecularity attached to hardened blood dirt on the blood vessel wall, carrying is in blood; be carried into again in the liver, decompose and excrete, repair the breakage of tunica intima simultaneously; recover blood vessel elasticity, blood vessel is recovered to greatest extent and protect.So many more coronary heart disease that are not easy to obtain more of this apolipoprotein.Scientists is referred to as it " anti-atherosis lipoprotein " or " the protection factor of coronary heart disease " " street cleaner in the blood vessel " or the like.
The World Health Organization (WHO) declares: widely accepting and the protectiveness factor of minimum dispute for cardiovascular and cerebrovascular vessel, is that serum high-density LP is high more good more.The Macro or mass analysis that american heart research institution does four large-scale prospective cardiovascular and cerebrovascular vessel institutes, the result shows: high density lipoprotein is every liter of serum rising 0.026mml in human body, can make coronary event incidence rate decline 2%-3%.So the intravital hdl level of people that significantly raises, can solve coronary heart disease, or even the problem of whole cardiovascular and cerebrovascular disease, can prolong decades to the mankind's life-span theoretically.
In the human body content of high density lipoprotein depend on the high density lipoprotein in the food content what.The content that improves the carnivorous thing middle-high density of fowl egg lipoprotein is the content optimal path that improves the human body high density lipoprotein, by high-density lipoprotein biological regulator the content of the high density lipoprotein in the animal is improved.From disclosed data, do not pick up rope at present as yet to this biological regulator.
Summary of the invention:
The object of the invention is to disclose a kind of production method of high-density lipoprotein biological regulator.
The primary raw material of biological regulator of the present invention and technological process are:
Raw material: alanine 2%; lysine 3%; ornithine 7%; glutamine 7%; phosphatide powder 10-15%; Radix Oenotherae erythrosepalae is by 5%; L-carnitine 3.8%; taurine 10%; acetylcholine 2%; the Radix Astragali 3%; Rhizoma Dioscoreae 3%; Rhizoma Chuanxiong 2%; Radix Rehmanniae Preparata 3%; Hirudo powder 2.93%; organic selenium 0.01%; tervalent organic chromium 0.01%; vitamin E--0.5%; nicotiamide--0.5%; vitamin B1--0.05%; vitamin B2--0.05%; vitamin B6--0.05%; vitamin B12--0.1%; all the other are the adequate proteins protein active peptide of full dissolubility--as complete molten soybean protein peptide.
Dosage form: can be the watered pill, tablet.
Watered pill technological process:
Mix and--pulverize----pill----oven dry--packing--sterilization--quality inspection---warehouse-in;
The tablet technological process:
--------packing--is sterilized--quality inspection---warehouse-in to beat sheet in pelletize in pulverizing in mixing.
The specific embodiment:
Embodiment 1
Raw material: alanine 2%; lysine 3%; ornithine 7%; glutamine 7%; phosphatide powder 10-15%; Radix Oenotherae erythrosepalae is by 5%; L-carnitine 3.8%; taurine 10%; acetylcholine 2%; the Radix Astragali 3%; Rhizoma Dioscoreae 3%; Rhizoma Chuanxiong 2%; Radix Rehmanniae Preparata 3%; Hirudo powder 2.93%; organic selenium 0.01%; tervalent organic chromium 0.01%; vitamin E--0.5%; nicotiamide--0.5%; vitamin B1--0.05%; vitamin B2--0.05%; vitamin B6--0.05%; vitamin B12--0.1%; all the other are the adequate proteins protein active peptide of full dissolubility--as complete molten soybean protein peptide.
Dosage form: can be the watered pill, tablet.
Watered pill technological process:
Mix and--pulverize----pill----oven dry--packing--sterilization--quality inspection----warehouse-in
The tablet technological process:
--------packing--is sterilized--quality inspection---warehouse-in to beat sheet in pelletize in pulverizing in mixing
Embodiment 2
Raw material: alanine 2%; lysine 3%; ornithine 7%; glutamine 7%; phosphatide powder 10-1 5%; Radix Oenotherae erythrosepalae is by 5%; L-carnitine 3.8%; taurine 10%; acetylcholine 2%; the Radix Astragali 3%; Rhizoma Dioscoreae 3%; Rhizoma Chuanxiong 2%; Radix Rehmanniae Preparata 3%; Hirudo powder 2.93%; organic selenium 0.01%; tervalent organic chromium 0.01%; vitamin E--0.5%; nicotiamide--0.5%; vitamin B1--0.05%; vitamin B2--0.05%; vitamin B6--0.05%; vitamin B12--0.1%; all the other are the adequate proteins protein active peptide of full dissolubility--as complete molten soybean protein peptide.
Dosage form: can be the watered pill, tablet.
Watered pill technological process:
Mix and--pulverize----pill----oven dry--packing--sterilization--quality inspection----warehouse-in
The tablet technological process:
--------packing--is sterilized--quality inspection---warehouse-in to beat sheet in pelletize in pulverizing in mixing
Following drinking water and above-mentioned regulator are used better effects if.: subset, alkalescence heavy-oxygen-enriched water.
Use raw material: tourmaline 15%, germanite 15%, zeolite 10%, Maifanitum 10%, Bal(n)phyllia sp. 15%, Muscovitum 10%, potter's clay 25%, rice husk powder 5% are produced water purification agent.
Be crushed to behind 5000 orders stand-by after above raw material mixed.Adding an amount of water becomes the mud shape to go into comminutor pelletize oven dry above raw material stirring.Exsiccant mudstone grain is gone into the calcining of drum-type calcining furnace, and effusive haydite can be to use water purification agent from calcining furnace.Water purification agent with 10% soaks water and can drink in 24 hours.Or water purification agent is added in the drainage screen of water dispenser according to the ratio that caliber 1T/ hour flow adds 100kg, effusive water is promptly drinkable.Or the 100g water treatment agent placed in the kettle, it is promptly drinkable to boil water.Amount of drinking water: about 3 liters of everyone every days.
The scope of application of this method
Be fit to all and contain simultaneously protein, triglycerides, cholesterol, phosphatide, high density lipoprotein level The animal body of white four key elements transforms. As: people, poultry, insect, aquatic products etc. It is amount Different with transformation time, day amount is per kilogram 0.3 gram of body weight.
Transformation time: people 30 days, poultry 15 days, fowl 15 days, insect 7 days, aquatic products 16 days. Eating method and effect: everyone 10g---20g every day, one after each meal; In human body, transformed in 30 days Go out HDL and surpass 200%; Transform content: the people surpasses 200%, and poultry surpasses 200%, fowl Surpass 200%, insect surpasses 100%, and aquatic products surpass 100%.
Claims (1)
1. the production method of a high-density lipoprotein biological regulator, raw material and technological process are:
Raw material: alanine 2%, lysine 3%, ornithine 7%, glutamine 7%, phosphatide powder 10-15%, Radix Oenotherae erythrosepalae is by 5%, L-carnitine 3.8%, taurine 10%, acetylcholine 2%, the Radix Astragali 3%, Rhizoma Dioscoreae 3%, Rhizoma Chuanxiong 2%, Radix Rehmanniae Preparata 3%, Hirudo powder 2.93%, organic selenium 0.01%, tervalent organic chromium 0.01%, vitamin E--0.5%, nicotiamide--0.5%, vitamin B1--0.05%, vitamin B2--0.05%, vitamin B6--0.05%, vitamin B12--0.1%, all the other are the adequate proteins protein active peptide of full dissolubility--as complete molten soybean protein peptide;
Dosage form: can be the watered pill, tablet;
Watered pill technological process:
Mix and--pulverize----pill----oven dry--packing--sterilization--quality inspection---warehouse-in;
The tablet technological process:
--------packing--is sterilized--quality inspection---warehouse-in to beat sheet in pelletize in pulverizing in mixing.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2007101444353A CN101167929A (en) | 2007-10-12 | 2007-10-12 | Method for producing high-density lipoprotein biological regulator |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2007101444353A CN101167929A (en) | 2007-10-12 | 2007-10-12 | Method for producing high-density lipoprotein biological regulator |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101167929A true CN101167929A (en) | 2008-04-30 |
Family
ID=39388777
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2007101444353A Pending CN101167929A (en) | 2007-10-12 | 2007-10-12 | Method for producing high-density lipoprotein biological regulator |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101167929A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103110114A (en) * | 2011-11-16 | 2013-05-22 | 北京康比特体育科技股份有限公司 | Beta-alanine-containing composition for endurance increase, and preparation thereof |
| CN103652948A (en) * | 2013-12-31 | 2014-03-26 | 陈慧婷 | Chinese yam and astragalus membranaceus dispersible tablets and preparation method thereof |
| CN104305197A (en) * | 2014-10-30 | 2015-01-28 | 四川力量科技有限公司 | Composition for increasing high-density lipoprotein |
-
2007
- 2007-10-12 CN CNA2007101444353A patent/CN101167929A/en active Pending
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103110114A (en) * | 2011-11-16 | 2013-05-22 | 北京康比特体育科技股份有限公司 | Beta-alanine-containing composition for endurance increase, and preparation thereof |
| CN103110114B (en) * | 2011-11-16 | 2014-05-28 | 北京康比特体育科技股份有限公司 | Beta-alanine-containing composition for endurance increase, and preparation thereof |
| CN103652948A (en) * | 2013-12-31 | 2014-03-26 | 陈慧婷 | Chinese yam and astragalus membranaceus dispersible tablets and preparation method thereof |
| CN103652948B (en) * | 2013-12-31 | 2015-06-17 | 陈慧婷 | Chinese yam and astragalus membranaceus dispersible tablets and preparation method thereof |
| CN104305197A (en) * | 2014-10-30 | 2015-01-28 | 四川力量科技有限公司 | Composition for increasing high-density lipoprotein |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1569123A (en) | Oral functional Chinese medicine intensified by snake, bee, macroelement and microelement and its preparation | |
| WO2020020183A1 (en) | Novel bamboo salt and preparation method therefor | |
| CN102232548A (en) | Cordyceps militaris-American ginseng capsule health-care product and preparation process thereof | |
| CN1350001A (en) | Fruit shell capable of being used to extract shinyleaf yellowhorn general saponin, coarse fat, coarse protein and sugar | |
| CN102008076B (en) | Egg albumen nutrition mixture beneficial to adjustment of immune function and preparation method thereof | |
| CN1245202C (en) | Medicine for preventing and treating bone fracture and osteoporosis | |
| KR101627837B1 (en) | Health supplement food comprising horse bone extracts as main ingredients and sea horse and manufacturing method for the same | |
| CN101129193B (en) | Compound high calcium tablet of yak medulla and method of preparing the same | |
| CN101536779B (en) | Glue series product | |
| CN105902567B (en) | A kind of concocting method of seven mineral grey of Tibetan medicine ingredient | |
| CN101167929A (en) | Method for producing high-density lipoprotein biological regulator | |
| CN106692361A (en) | Fagopyrum tataricum composition, preparation method thereof, preparations and application | |
| JP2005060357A (en) | Health food for promoting sleep and tranquirizing by using plant as raw material and method for producing the same | |
| CN101664180A (en) | Health-care nutritional complexing agent with effect of and preparation method thereof | |
| CN101422544A (en) | Haifei capsule formulation with weight reduction function and preparation method thereof | |
| CN110051817A (en) | A kind of Chinese traditional medicine composition and its application reducing uric acid | |
| CN107320569A (en) | A kind of flat fat chewable tablets and preparation method thereof | |
| KR19980038121A (en) | Method of manufacturing functional foods (materials) mainly containing fish vinegar and seaweed | |
| CN105559060B (en) | A kind of beneficial spleen stomach invigorating filefish fish oil health-caring capsule | |
| CN110558568A (en) | functional food for reducing high blood pressure, high blood sugar and preparation method thereof | |
| CN1660207A (en) | Preparation of health care for reducing blood fat and cholesterol, and producing method | |
| CN1126597A (en) | Loach powder and its prepn process and application | |
| CN1270737C (en) | Drug for treating gout and method for preparing pill thereof | |
| CN100450493C (en) | Black fungus composite soft capsule and its preparing process | |
| CN109805311A (en) | The health care product of the anti-anti- breast cancer of nitrosamine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Open date: 20080430 |